Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Ychou

Showing results (71-80 of 103) with videos related to

Pageof 11
Sort By:
British Journal of Cancer|October 9, 2008
Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancerT Conroy, F Viret, E François, et al.
European Journal of Cancer (Oxford, England : 1990)|January 29, 2013
Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study)M Ducreux, A Adenis, J-P Pignon, et al.
International Journal of Cancer|February 18, 1998
Phase-I/II radio-immunotherapy study with Iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab')2 in patients with non-resectable liver metastases from colorectal cancerM Ychou, A Pelegrin, P Faurous, et al.
European Journal of Cancer (Oxford, England : 1990)|March 12, 2017
Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapiesM Del Rio, C Mollevi, F Bibeau, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 10, 1998
Simultaneous high-dose external irradiation and daily cisplatin in unresectable, non-metastatic adenocarcinoma of the pancreas: a phase I-II studyT D Nguyen, S Theobald, P Rougier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2003
Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancerD Fallik, M Ychou, J Jacob, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 6, 2015
Postoperative irinotecan in resected stage II-III rectal cancer: final analysis of the French R98 Intergroup trial†C Delbaldo, M Ychou, A Zawadi, et al.
Cancer Chemotherapy and Pharmacology|November 20, 2002
High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancerM Ychou, J L Raoul, F Desseigne, et al.
The Pharmacogenomics Journal|July 21, 2010
A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancerA Ho-Pun-Cheung, E Assenat, C Bascoul-Mollevi, et al.
Pancreas|September 26, 2003
Docetaxel and radiotherapy and pancreatic cancerF Viret, M Ychou, A Gonçalves, et al.
Pageof 11

Showing results (71-80 of 103) with videos related to

Sort By:
Pageof 11
British Journal of Cancer|October 9, 2008
Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancerT Conroy, F Viret, E François, et al.
European Journal of Cancer (Oxford, England : 1990)|January 29, 2013
Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study)M Ducreux, A Adenis, J-P Pignon, et al.
International Journal of Cancer|February 18, 1998
Phase-I/II radio-immunotherapy study with Iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab')2 in patients with non-resectable liver metastases from colorectal cancerM Ychou, A Pelegrin, P Faurous, et al.
European Journal of Cancer (Oxford, England : 1990)|March 12, 2017
Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapiesM Del Rio, C Mollevi, F Bibeau, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 10, 1998
Simultaneous high-dose external irradiation and daily cisplatin in unresectable, non-metastatic adenocarcinoma of the pancreas: a phase I-II studyT D Nguyen, S Theobald, P Rougier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2003
Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancerD Fallik, M Ychou, J Jacob, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 6, 2015
Postoperative irinotecan in resected stage II-III rectal cancer: final analysis of the French R98 Intergroup trial†C Delbaldo, M Ychou, A Zawadi, et al.
Cancer Chemotherapy and Pharmacology|November 20, 2002
High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancerM Ychou, J L Raoul, F Desseigne, et al.
The Pharmacogenomics Journal|July 21, 2010
A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancerA Ho-Pun-Cheung, E Assenat, C Bascoul-Mollevi, et al.
Pancreas|September 26, 2003
Docetaxel and radiotherapy and pancreatic cancerF Viret, M Ychou, A Gonçalves, et al.
Pageof 11